Clinical response to alefacept: Results of a phase 3 study of intravenous administration of alefacept in patients with chronic plague psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 17, Issue SUPPL. 2, 2003, Pages 17-24

  Krueger, G G ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Alefacept; CD4+CD45RO+ memory effector T cells; PASI; Psoriasis

Indexed keywords

ALEFACEPT; PLACEBO;

ADULT; AGED; ARTICLE; CANADA; CHILL; CHRONIC DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; INFECTION; INJURY; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PATIENT SELECTION; PHARMACODYNAMICS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINITIS; T LYMPHOCYTE; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL AVAILABILITY; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0037592156     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.17.s2.4.x     Document Type: Article

References (9)

1. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999; 341: 1817-1828.
2. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
3. Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132:623-629.
4. Wollina U, Stander K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis-short-and long-term toxicity in 104 patients. Clin Rheumatol 2001; 20: 406-410.
5. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-761.
6. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998; 90: 1278-1284.
7. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994; 152: 2753-2767.
8. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
9. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-255.